Express Pharma
AUGUST 19, 2024
Nadda further stated, “India has always been the world leader in the production and supply of vaccines contributing to approximately 60 per cent of the global supply of vaccines.” He explained that the World Health Organization procures 70 per cent of its vaccine demand from India.
Express Pharma
APRIL 16, 2024
As the world’s leading supplier of generic drugs, India’s pharmaceutical industry has become a ray of hope for millions as it ensures quality-assured and cost-effective treatments reach those who need them the most. It also contributes to 40 per cent of medications in the US and 33 per cent in the EU.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 29, 2022
With the rapid onset of the pandemic, the race to develop a viable vaccine quickly became a race to secure access to the developed vaccines. In this article, Ben Hargreaves examines how wealth determined the winners and what is now underway to help lower-income countries gain access to the available vaccines.
pharmaphorum
OCTOBER 17, 2022
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of Takeda GmbH’s live, attenuated dengue tetravalent vaccine, Qdenga ( TAK-003 ). Medicines submitted under EU-M4all are assessed by the CHMP in collaboration with the WHO and target countries.
Express Pharma
MAY 10, 2024
As the world’s leading supplier of generic drugs, India’s pharmaceutical industry has become a ray of hope for millions as it ensures quality-assured and cost-effective treatments reach those who need them the most. The country accounts for 20 per cent of the world’s generic drugs and 60 per cent of the global vaccine supply.
European Pharmaceutical Review
JULY 1, 2024
the CHMP gave a positive opinion for the first nasally administered emergency treatment for allergic reactions” A positive opinion was granted to the mResvia (Respiratory Syncytial Virus (RSV) mRNA vaccine). Eurneffy (epinephrine) offers an alternative method to the standard injection method of administration. 1 virus variant.
European Pharmaceutical Review
SEPTEMBER 21, 2022
Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. Adapted vaccines Comirnaty Original/Omicron BA.1 Adapted vaccines Comirnaty Original/Omicron BA.1
Expert insights. Personalized for you.
99 
Let's personalize your content